Medicinal and Biological Chemistry of Alkynylgold Complexes

炔基金（I）配合物是一种在催化和电子学中具有广泛用途的有机金属配合物。然而，它们在接近化学的生物医学科学（特别是药物化学和化学生物学）中的适用性最近才在第一次试点研究中得到证明。金（I）与炔基配体的稳定配位导致具有药物开发潜力的络合物。特别令人感兴趣的是对硫氧还蛋白还原酶的强烈和选择性抑制，硫氧还蛋白还原酶是新型抗癌药物候选物的分子靶标。这种类型的有机金属化合物的生物化学-生物学潜力仍然是相当未开发的。在第一个项目阶段，对炔基金（I）配合物的药物化学有了更深入的了解。在第二个项目阶段，额外的结构-活性-关系研究以及药物分析和生物分析将成为重点，旨在将这类化合物过渡到药物开发阶段。

Alkynylgold(I) complexes are organometallic species with a broad usage in catalysis and in electronics. However, their applicability in biomedical sciences close to chemistry (in particular Medicinal Chemistry and Chemical Biology) has only recently been demonstrated within first pilot studies. The stable coordination of gold(I) to the alkynyl ligand leads to complexes with a promising potential for drug development. Of particular interest is the strong and selective inhibition of the enzyme thioredoxin reductase, which is a molecular target for novel anticancer drug candidates. The biochemical-biological potential of this type of organometallics is still rather unexplored. During the first project phase a deeper understanding of the medicinal chemistry of alkynylgold(I) complexes was achieved. Within the second project phase additional structure-activity-relationship studies as well as pharmaceutical analytics and bioanalytics will be in the focus aiming at a transition of this class of compounds to the drug development stage.